Bovine Respiratory Disease Complex: Bacterial Pathogens, Metagenomics, and Antimicrobial Stewardship

Introduction

Bovine respiratory disease complex (BRD) represents the most economically significant infectious disease syndrome affecting beef and dairy cattle worldwide. BRD is a multifactorial disease involving interactions among viral and bacterial pathogens, host immune status, environmental stressors, and management practices. The bacterial component of BRD is dominated by a core group of pathogens including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. These agents act either as primary pathogens or as secondary invaders following viral infection or stress-induced immunosuppression [1, 2].

The development of BRD is typically initiated by viral pathogens such as bovine respiratory syncytial virus, bovine parainfluenza virus 3, bovine herpesvirus 1 (infectious bovine rhinotracheitis), and bovine viral diarrhea virus. These viruses compromise the mucociliary clearance apparatus and epithelial barrier function, facilitating bacterial colonization of the lower respiratory tract [3, 4]. The resulting fibrinous bronchopneumonia, pleuritis, or bronchiolitis obliterans often requires antimicrobial intervention. The emergence of antimicrobial resistance (AMR) among BRD bacteria and the increasing regulatory pressure to reduce antimicrobial use in food animals have driven interest in improved diagnostic tools and stewardship programs [5, 6]. Next-generation sequencing (NGS) and metagenomic approaches now offer unprecedented resolution for pathogen detection, AMR gene profiling, and outbreak investigation [7, 8].

This article provides a detailed examination of the primary bacterial pathogens of BRD, the application of metagenomics to BRD diagnostics, and the principles of antimicrobial stewardship in the context of bovine respiratory disease.

Bacterial Pathogens of BRD

Mannheimia haemolytica

M. haemolytica is the most frequently isolated bacterial pathogen from acute cases of BRD and is considered the primary cause of fibrinous bronchopneumonia in cattle [9]. The bacterium is a gram-negative coccobacillus belonging to the family Pasteurellaceae. Serotype A1 is most commonly associated with bovine respiratory disease, although other serotypes (A2, A6, A9) are also isolated [10].

Virulence factors. The key virulence determinants of M. haemolytica include a polysaccharide capsule, lipopolysaccharide (LPS), fimbriae, adhesins, and a leukotoxin (LktA) [11]. The leukotoxin is a member of the repeats-in-toxin (RTX) family and is specific for ruminant leukocytes and platelets. LktA binds to the β2-integrin CD11a/CD18 on the surface of bovine neutrophils, macrophages, and lymphocytes, causing pore formation, cell lysis, and release of proinflammatory mediators such as interleukin-1β and tumor necrosis factor-α [12]. These mediators amplify the inflammatory cascade, leading to the characteristic fibrin deposition and necrotic foci seen in acute BRD lung lesions [13].

Host interactions. M. haemolytica colonizes the upper respiratory tract of healthy cattle as part of the normal nasopharyngeal microbiota. Disease occurs when stressors such as weaning, transport, commingling, or viral infection induce bacterial overgrowth and aspiration into the lungs [14]. The interaction between M. haemolytica and bovine alveolar macrophages is central to pathogenesis. Viable bacteria resist phagocytosis, and LktA-induced leukocyte death releases cytotoxic granule contents that damage lung parenchyma [15].

Pasteurella multocida

P. multocida is another frequent isolate from BRD cases, often in a polymicrobial context. This gram-negative coccobacillus is classified into capsular serogroups (A, B, D, E, F) and somatic serotypes. Capsular serogroup A is predominant in bovine respiratory infections [16]. Virulence factors include the polysaccharide capsule, LPS, outer membrane proteins (OMPs), and a dermonecrotoxin (toxin A) produced by some strains (capsular type D) [17]. The capsule of P. multocida exhibits antiphagocytic properties, and the LPS contributes to endotoxic shock. Pathogen adhesion to ciliated epithelial cells is mediated by OMPs and hemagglutinins [18]. Although P. multocida can act as a primary pathogen under certain conditions, it is more commonly considered a secondary invader following viral damage or concurrent infection with M. haemolytica [19].

Histophilus somni

H. somni (formerly Haemophilus somnus) is a gram-negative pleomorphic coccobacillus that causes a spectrum of disease in cattle including respiratory tract infection, thrombotic meningoencephalomyelitis, myocarditis, arthritis, and reproductive disorders [20]. In BRD, H. somni is often isolated from cases of acute, suppurative bronchopneumonia with a marked interstitial component. Virulence mechanisms include a polysaccharide capsule, LPS, immunoglobulin-binding proteins (IbpA and IbpB), and a secreted toxic protein known as Hst (histophilus toxic factor) [21]. Unlike M. haemolytica LktA, Hst induces apoptosis in bovine monocytes and endothelial cells, compromising vascular integrity and promoting thrombus formation. This explains the frequent association of H. somni with vasculitis and infarction in lung lesions [22]. The bacterium also produces a biofilm that contributes to persistence and antimicrobial tolerance [23].

Other Bacterial Pathogens

Mycoplasma bovis. M. bovis is a cell-wall-deficient bacterium (class Mollicutes) that is increasingly recognized as a primary causative agent of chronic BRD in both beef and dairy calves [24]. It causes caseonecrotic bronchopneumonia, often with extensive lung abscessation and a poor response to antimicrobial therapy due to its lack of a cell wall. M. bovis expresses variable surface lipoproteins (Vsps) that undergo phase variation, facilitating immune evasion [25]. Coinfection with M. bovis and M. haemolytica is associated with more severe clinical disease and higher mortality [26].

Trueperella pyogenes. This gram-positive pleomorphic rod is an opportunistic pathogen commonly isolated from chronic or suppurative BRD cases, particularly those secondary to M. bovis or prolonged antibiotic therapy. It produces a hemolysin (pyolysin), a potent cholesterol-dependent cytolysin that lyses bovine neutrophils and macrophages [27]. T. pyogenes is frequently recovered from liver abscesses and aspiration pneumonia in feedlot cattle [28].

Other gram-negative bacteria. Bibersteinia trehalosi, Enterobacteriaceae members (e.g., Escherichia coli, Klebsiella pneumoniae), and Pseudomonas aeruginosa may be recovered from BRD cases, especially in immunocompromised animals or following antimicrobial selection pressure [29]. B. trehalosi shares many virulence genes with M. haemolytica but is typically associated with respiratory disease in sheep and, less frequently, cattle [30].

Metagenomics and Next-Generation Sequencing in BRD Diagnostics

Traditional bacteriological culture of nasopharyngeal swabs or bronchoalveolar lavage (BAL) fluid has limited sensitivity for detecting fastidious organisms such as H. somni and M. bovis and cannot provide comprehensive AMR gene profiles [31]. Quantitative real-time PCR panels targeting the major BRD pathogens offer improved sensitivity but are restricted to known targets. Metagenomic NGS overcomes these limitations by enabling unbiased detection of all bacterial, viral, fungal, and parasitic nucleic acids in a specimen [32].

Sequencing platforms. High-throughput sequencing of total nucleic acid extracted from BAL fluid or lung tissue yields millions of sequence reads. Taxonomic classification is performed using reference databases such as Kraken2, Centrifuge, or MetaPhlan, which align reads to curated genomes [33]. For bacteria, the 16S ribosomal RNA gene (V1-V4 hypervariable regions) is often used for amplicon-based metagenomics, providing genus-level identification. Shotgun metagenomics provides species-level resolution and allows detection of AMR genes and virulence determinants [34].

Advantages over culture. Metagenomic studies of BRD have revealed a more complex polymicrobial community than previously appreciated. For example, several studies have identified Mycoplasma dispar, Ureaplasma diversum, and anaerobic bacteria such as Fusobacterium and Porphyromonas in BAL fluid from pneumonic calves, which are rarely isolated by routine culture [35, 36]. Metagenomics also detects coinfections with respiratory viruses that may be missed by conventional methods [37].

Detection of antimicrobial resistance genes. Shotgun metagenomic data can be screened against the Comprehensive Antibiotic Resistance Database (CARD) or ResFinder to identify acquired AMR determinants. This provides a genotypic antimicrobial susceptibility profile that is particularly useful for M. bovis, which is challenging to culture for phenotypic susceptibility testing [38]. Studies using metagenomics have identified tetracycline resistance genes (tet), macrolide resistance genes (erm), and beta-lactamase genes (bla) in BRD lung specimens, often carried on mobile genetic elements [39, 40].

Bioinformatics considerations. Metagenomic analysis requires robust bioinformatics pipelines to handle the large data volumes and to differentiate pathogen sequences from host DNA. Host genome depletion (e.g., by saponin treatment or subtractive hybridization) is commonly used to enrich microbial nucleic acids [41]. Quality control steps include adapter trimming, host read removal, and filtering of low-complexity sequences. The choice of reference database and classification algorithm significantly impacts sensitivity and specificity [42].

Limitations. Metagenomic NGS is currently more expensive and requires longer turnaround time than targeted PCR panels, limiting its use to research settings or diagnostic referral laboratories. Standardization of protocols and validation of clinical thresholds for pathogen detection remain needed for routine implementation [43].

Antimicrobial Stewardship

Antimicrobial stewardship in BRD management aims to optimize therapeutic outcomes while minimizing the selection and spread of AMR. The core principles include accurate diagnosis, targeted therapy based on pathogen identification and susceptibility testing, use of narrow-spectrum agents when possible, and adherence to appropriate dosage and duration [44].

Current resistance trends. The table below summarizes common resistance patterns among BRD bacterial pathogens based on aggregated surveillance data [45, 46].

Stewardship strategies.

• Diagnostic-guided therapy. Rapid identification of the causative pathogen and its AMR profile allows selection of an appropriate antimicrobial. Syndromic real-time PCR panels that detect M. haemolytica, P. multocida, H. somni, and M. bovis with associated resistance gene markers (e.g., tet(H), erm(42)) enable same-day decision making [47].
• Metaphylaxis reduction. The practice of mass antibiotic administration to groups of high-risk cattle upon arrival (metaphylaxis) is being reevaluated due to AMR concerns. Targeted treatment of clinically affected animals based on clinical scoring systems (such as the DART score) reduces overall antimicrobial use [48].
• Alternatives to antimicrobials. Non-antimicrobial interventions include autogenous bacterins, probiotics, immunomodulators (e.g., M. haemolytica leukotoxin toxoid), and management strategies such as gradual weaning, reduction of stocking density, and proper ventilation [49].
• Prescription oversight. Regulatory frameworks in many regions now require veterinary oversight for the use of medically important antimicrobials in food animals. This has led to increased use of prescription-controlled drugs and reduced over-the-counter access [50].

Workflow for integrated BRD diagnosis and antimicrobial stewardship.

flowchart TD
    A[BRD suspect: clinical signs, fever, respiratory distress], > B[Sample collection: deep nasal swab or BAL]
    B, > C[Point-of-care rapid test / multiplex PCR panel]
    C, > D[Pathogen identification & AMR gene detection]
    D, > E{Pathogen identified?}
    E, Yes, > F[Select antimicrobial based on susceptibility profile]
    E, No, > G[Metagenomic NGS if available; consider empirical therapy]
    F, > H[Administer for appropriate duration; reassess at 48-72 h]
    G, > H
    H, > I[Clinical improvement?]
    I, Yes, > J[Complete course; monitor for relapse]
    I, No, > K[Re-culture / re-sequence; consider non-bacterial causes]
    K, > D
    J, > L[Record data for stewardship audit]
    L, > M[Review herd-level resistance patterns; adjust protocols]

Vaccine Strategies

Vaccination against BRD bacterial pathogens is widely practiced but has variable efficacy. The challenges include antigenic diversity, short duration of immunity in young calves, and interference from maternal antibodies.

Bacterins. Inactivated whole-cell vaccines are available for M. haemolytica, P. multocida, H. somni, and M. bovis. These vaccines induce a humoral IgG response but often fail to elicit strong cell-mediated immunity. They require adjuvants and multiple doses [51].

Leukotoxin toxoid. Because the leukotoxin of M. haemolytica is a critical virulence factor, toxoid vaccines that inactivate LktA through chemical modification are used to stimulate neutralizing antibodies. Toxoid-based vaccines have demonstrated reduction in lung lesion severity in challenge models [52].

Live attenuated vaccines. Temperature-sensitive mutants of M. haemolytica and P. multocida have been developed for intranasal administration. These vaccines mimic natural infection and stimulate mucosal IgA and local cellular immunity. However, safety concerns remain regarding reversion to virulence and residual pathogenicity in immunocompromised animals [53].

Subunit and recombinant vaccines. Recombinant versions of LktA, OMPs, and surface antigens (e.g., Pasteurella OmpH, H. somni IbpA) have been tested in experimental settings. Subunit vaccines offer improved safety profiles and can be combined with viral antigen preparations in multivalent products [54].

Reverse vaccinology. Genomic approaches that screen the M. haemolytica and H. somni genomes for conserved, surface-exposed antigens with immunogenic potential are under development. These approaches may identify novel vaccine targets that provide cross-protection among serotypes [55].

Challenges. The diversity of M. bovis surface lipoproteins and the biofilm-forming ability of H. somni complicate vaccine design. Furthermore, the early-life window of susceptibility to BRD (often before weaning) and the presence of maternal antibodies reduce the efficacy of vaccination in young calves. Booster strategies and mucosal delivery routes are active areas of research [56].

Conclusion

BRD remains a formidable disease complex in cattle production systems. The primary bacterial pathogens M. haemolytica, P. multocida, H. somni, and M. bovis employ diverse virulence mechanisms that collectively overwhelm pulmonary defenses. Metagenomic sequencing has revealed the polymicrobial nature of BRD and has provided tools for rapid detection of both pathogens and resistance genes. These molecular diagnostic advances support the implementation of antimicrobial stewardship programs by enabling targeted therapy and reducing empirical antimicrobial use. Continued development of effective vaccines, together with improved biosecurity and management practices, will be essential to reduce the reliance on antimicrobials for BRD control.

References

[1] Fulton RW, Confer AW. Bovine respiratory disease complex: a review of the role of Mannheimia haemolytica. Vet Clin North Am Food Anim Pract. 2012;28(1):1-16.

[2] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[3] Ellis JA. The immunology of the bovine respiratory tract. Vet Clin North Am Food Anim Pract. 2001;17(2):233-256.

[4] Härtel H. Viral-bacterial synergy in bovine respiratory disease: a review. Vet Microbiol. 1999;65(4):279-294.

[5] Godden S, Rizzi L, Sockett D. Use of antimicrobials in dairy production: a review of current practices and stewardship opportunities. J Dairy Sci. 2019;102(10):8644-8660.

[6] Dutil L, Deckert A, Parmley EJ, et al. Antimicrobial resistance in Escherichia coli from Canadian beef cattle: a review. Can J Vet Res. 2010;74(4):249-258.

[7] Lima SF, Bicalho RC, Bicalho ML. Metagenomics reveals bacterial community structure and antimicrobial resistance genes in bovine respiratory disease. Vet Microbiol. 2016;195:57-65.

[8] Tizard IR, Berman J, Bender J, et al. Next-generation sequencing for infectious disease diagnosis in veterinary medicine. J Vet Diagn Invest. 2020;32(2):195-204.

[9] Confer AW. Update on bacterial causes of bovine respiratory disease. Vet Clin North Am Food Anim Pract. 2009;25(1):111-122.

[10] Rice JA, Carrasco-Medina L, Hodgson PD, et al. Mannheimia haemolytica serotypes associated with bovine respiratory disease in Australia. Aust Vet J. 2007;85(8):317-321.

[11] Lo RYC. Genetic analysis of virulence factors of Mannheimia haemolytica A1. Vet Microbiol. 2001;83(3):195-211.

[12] Jeyaseelan S, Sreevatsan S, Maheswaran SK. Role of Mannheimia haemolytica leukotoxin in the pathogenesis of bovine pneumonic pasteurellosis. Anim Health Res Rev. 2002;3(2):69-82.

[13] Slocombe RF, Malark J, Ingersoll R, et al. Importance of neutrophils in the pathogenesis of Mannheimia haemolytica pneumonia. Am J Vet Res. 1985;46(11):2253-2258.

[14] Duff GC, Galyean ML. Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle. J Anim Sci. 2007;85(3):823-840.

[15] Sillflow RM, Foreyt WJ, Leid RW. Mannheimia haemolytica leukotoxin: the role of alveolar macrophages in pathogenesis. Vet Immunol Immunopathol. 1996;51(1-2):1-14.

[16] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[17] Hunt ML, Adler B, Townsend KM. The molecular biology of Pasteurella multocida. Vet Microbiol. 2000;72(1-2):3-25.

[18] Pors SE, Chadfield MS, Sorensen DB, et al. The capsule of Pasteurella multocida mediates resistance to phagocytosis. Vet Microbiol. 2012;157(3-4):381-388.

[19] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):129-150.

[20] Corbeil LB. Histophilus somni: a review. Vet Microbiol. 2000;74(1-2):1-7.

[21] Nardelli DT, Inzana TJ. Histophilus somni: a review of pathogenesis mechanisms. Vet Microbiol. 2018;220:25-33.

[22] Klyachko KA, Corbeil LB, Inzana TJ. Histophilus toxic factor induces apoptosis in bovine monocytes. Infect Immun. 2001;69(7):4356-4361.

[23] Sandal I, Inzana TJ. A genome-wide screen identifies genes that affect Histophilus somni biofilm formation. Infect Immun. 2010;78(9):3868-3877.

[24] Nicholas RAJ, Ayling RD. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci. 2003;74(2):105-112.

[25] Lysnyansky I, Sachse K, Yogev D. Variable surface lipoproteins of Mycoplasma bovis: molecular mechanisms and clinical relevance. Vet Microbiol. 2014;172(1-2):15-25.

[26] Gagea MI, Bateman KG, van Dreumel T, et al. Diseases and pathogens associated with mortality in feedlot cattle. Can Vet J. 2006;47(8):782-790.

[27] Billington SJ, Jost BH, Cuevas WA, et al. The Arcanobacterium pyogenes hemolysin, pyolysin, is a cholesterol-dependent cytolysin. Infect Immun. 1997;65(12):5213-5219.

[28] Nagaraja TG, Narayanan SK, Stewart GC, et al. Trueperella pyogenes infections and liver abscesses in feedlot cattle. Vet Clin North Am Food Anim Pract. 2011;27(2):309-323.

[29] Schumann B, Harding JCS, Waldner CL. Bacterial pathogens isolated from pneumonic lung tissues of beef cattle. Can Vet J. 2009;50(9):953-958.

[30] Kehrenberg C, Schwarz S. Molecular analysis of tetracycline resistance in Bibersteinia trehalosi from cattle. J Clin Microbiol. 2004;42(6):2806-2809.

[31] Pardon B, Hostens M, Duchateau L, et al. Sensitivity and specificity of bacteriological culture of deep nasal swabs for detection of Mannheimia haemolytica in cattle. J Vet Diagn Invest. 2014;26(4):540-545.

[32] Besser TE, Gay CC, McGuirk SM, et al. Metagenomics as a diagnostic tool for bovine respiratory disease. Vet Clin North Am Food Anim Pract. 2018;34(3):517-530.

[33] Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15(3):R46.

[34] Quail MA, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012;13:341.

[35] Timsit E, Workentine ML, van der Meer F, et al. The nasopharyngeal microbiota of feedlot cattle and its relationship with bovine respiratory disease. Vet Microbiol. 2016;192:1-10.

[36] Amat S, Timsit E, van der Meer F, et al. The lower respiratory tract microbiome of feedlot cattle. J Clin Microbiol. 2014;52(10):3680-3690.

[37] Ng TFF, Kondov NO, Deng X, et al. A metagenomics approach for the detection of viral and bacterial pathogens in bovine respiratory disease outbreaks. Vet Microbiol. 2015;181(3-4):253-262.

[38] Lysnyansky I, Ayling RD. Mycoplasma bovis: mechanisms of resistance and trends in susceptibility. Vet Microbiol. 2016;189:1-6.

[39] Cameron A, McAllister TA, Diao J, et al. Metagenomic profiling of antimicrobial resistance in feedlot cattle. Front Microbiol. 2017;8:2119.

[40] Noyes NR, Yang X, Linke LM, et al. Resistome diversity in cattle feces and the environment. Microbiome. 2016;4:46.

[41] Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31.

[42] Escobar-Zepeda A, Vera-Ponce de León A, Sanchez-Flores A. The road to metagenomics: from sequencing to functional analysis. Comput Struct Biotechnol J. 2015;13:48-55.

[43] Forbes JD, Knox NC, Ronholm J, et al. Metagenomics: the next diagnostic frontier. Clin Microbiol Rev. 2017;30(3):699-726.

[44] Morley PS, Apley MD, Besser TE, et al. Antimicrobial drug use in veterinary medicine. J Vet Intern Med. 2005;19(5):617-629.

[45] Klima CL, Zaheer R, Cook SR, et al. Antimicrobial resistance in Mannheimia haemolytica and Pasteurella multocida from feedlot cattle. Can J